How to Sell With Slowing Growth: Defending Your Healthcare Company Multiple
Key Takeaways
- Slowing growth does not automatically destroy value when the business still shows resilience, stability, and strategic relevance.
- Buyers continue to reward durable earnings because consistency often matters more than short-term momentum.
- Clean, credible data strengthens valuation defense by giving buyers less room to question performance.
- A clear growth story reduces pressure in negotiations and helps frame a slowdown in the right strategic context.
- Preparation protects your multiple by turning uncertainty into confidence before buyers use it against you.
Why Slowing Growth Does Not Kill Value
A slowdown in growth can make owners nervous, but it does not automatically mean buyers will slash valuation. In healthcare M&A, quality still matters more than panic. If your margins, retention, and operations remain solid, a slower period can still support a strong outcome. That is why selling when growth slows requires better positioning, not weaker expectations.
What Buyers Actually Underwrite
EBITDA Durability Matters More
When topline momentum cools, buyers spend more time testing whether earnings can hold through reimbursement pressure, labor costs, and operating friction. They want proof that performance is stable and transferable after closing. That is why disciplined diligence and controlled buyer communication matter so much in keeping buyers honest through close.
The Market Still Rewards Resilience
Recent market data shows healthcare investors are still active, but they are concentrating capital in stronger, more strategic assets instead of paying premium prices for every growth story. Bain reports that healthcare private equity deal value rose sharply in 2025 even as buyers stayed selective, which supports the idea that resilient businesses can still defend strong multiples in a slower-growth market.
The First Rule of Multiple Defense
Before going to market, owners should prove that slower growth is temporary, explainable, and manageable. Buyers lower multiples fastest when they see confusion, inconsistent data, or a weak explanation. A seller who prepares the story early can protect both credibility and price by avoiding preventable concerns later in the process, and seller due diligence with preemptive fixes supports that point directly.
The Metrics That Protect Your Multiple
When growth slows, buyers stop rewarding broad promises and start measuring the quality of the business underneath the revenue line. They want to see stable patient demand, clean reporting, manageable churn, and a business that still looks attractive after closing. That is why setting a realistic valuation range without underselling becomes more important when momentum is softer, and every number gets tested more closely.
How to Explain the Slowdown
A slowdown is easier to defend when management can explain it clearly and back the explanation with facts. If the cause is provider recruiting delays, reimbursement timing, payer changes, or a deliberate operational reset, the story should be consistent across the CIM, seller memo, and management calls. Recent KPMG analysis on healthcare M&A strategic recalibration supports that approach because buyers are still active, but they are screening assets more carefully and rewarding clearer positioning in a more selective market
Buyers Still Pay for Quality
Recent Bain data shows global healthcare private equity deal value exceeded an estimated $191 billion in 2025, with 445 buyouts, the second-highest annual total on record. That matters because buyers are still willing to pay for healthcare assets, but they are concentrating attention on stronger companies with resilient earnings, clearer strategy, and lower execution risk, which is why how healthcare advisors convert operational metrics into valuation premiums works better here than a broad growth story alone.
Why Process Quality Changes Price
A seller with slowing growth cannot afford a messy process. Weak materials, inconsistent KPIs, and vague answers create buyer leverage fast. A cleaner process keeps the focus on transferable value instead of avoidable doubt. KPMG’s guidance on laying the foundations for a successful M&A process reinforces the same point: thorough preparation across operational, financial, legal, and tax issues helps protect value before buyer pressure builds.
How to Reduce Discount Risk
If growth has slowed, the goal is not to pretend everything is perfect. The goal is to show buyers that the slowdown is understood, contained, and fixable. That usually means cleaning up reporting, tightening forecasts, and presenting a sharper operating story before launch. MedBridge makes that point clearly in responding to buyer requests without appearing defensive, where preparation is positioned as a value-protection tool, not just a diligence task.
Build Proof Before You Go to Market
A seller with slowing growth should not rely on optimism alone. Buyers want evidence: stable retention, credible explanations for recent softness, and a plan for margin support after closing. That is why seller due diligence and preemptive fixes matter so much. Fixing preventable issues before buyers find them reduces retrade risk and keeps attention on the company’s underlying strengths instead of avoidable weaknesses.
Strong Assets Still Attract Buyers
The broader market still supports well-prepared healthcare sellers. McKinsey reported on February 13, 2026, that US healthcare dealmaking in 2025 remained stable relative to 2023 and 2024, with buyers continuing to pursue transactions that add capabilities and strengthen existing portfolios. That supports a practical conclusion for owners: slower growth does not automatically kill value if the business still fits what buyers are actively trying to build.
Conclusion
Defending your multiple in a slower-growth market comes down to proof, discipline, and positioning. Buyers may challenge momentum, but they still pay for resilience, clarity, and lower risk. That is why process control matters so much. MedBridge’s recent piece on avoiding deal fatigue with process discipline reinforces the same lesson: stronger preparation helps sellers protect leverage when buyers become more selective.
FAQs
1. Does slower growth always reduce valuation?
No. Buyers often look deeper at EBITDA durability, retention, and operational quality before deciding whether slower growth really changes value.
2. What hurts multiples most in a slowdown?
Messy reporting, inconsistent explanations, margin pressure, and unresolved diligence risks usually hurt more than a slowdown alone.
3. Can a healthcare company still sell well with flat growth?
Yes. If earnings are stable and the business fits buyer’s strategy, flat or slower growth can still support strong interest.
4. Should owners wait for growth to rebound before selling?
Not always. Sometimes preparation, positioning, and buyer fit matter more than waiting for perfect timing.
5. What is the best defense against retrades?
Clean data, a credible narrative, and preemptive diligence work usually give sellers the best protection.